An Increase in Demand and Opportunities for the Global Orally Disintegrating Tablet Market by 2024,” offers a comprehensive analysis of the market by evaluating research and information from multiple ...
MALVERN, Pa., Nov. 18, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary ...
The company has issued a voluntary recall of one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV), because of incorrect strength published on product carton. FDA announced on July 17, 2024 ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today ...
Dr. Ofer Agid, Medical Head of Ambulatory Services in the Schizophrenia Division at the Centre for Addiction and Mental Health (CAMH) in Toronto, commented, "The introduction of Gen-Clozapine is ...
ENGLEWOOD, CO / ACCESSWIRE / January 10, 2023 / Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them are currently struggling ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback